Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
← catalyst calendarNCT05210803 · readout ≤ 1,807 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With REGENXBIO Inc..
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
116estimated
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-20 | actual | When the study began enrolling |
| Primary completion | Jul 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
- Drug: Standard of Care
- Drug: Ranibizumab — also filed as LUCENTIS
Primary outcome
what the primary-completion date above is the date OFIncidences of ocular Adverse Events and any Serious Adverse Events
measured 5 years inclusive of parent study
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed